387 related articles for article (PubMed ID: 30307529)
41. Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles.
Dubois S; Tesson B; Mareschal S; Viailly PJ; Bohers E; Ruminy P; Etancelin P; Peyrouze P; Copie-Bergman C; Fabiani B; Petrella T; Jais JP; Haioun C; Salles G; Molina TJ; Leroy K; Tilly H; Jardin F;
EBioMedicine; 2019 Oct; 48():58-69. PubMed ID: 31648986
[TBL] [Abstract][Full Text] [Related]
42. The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.
Keane C; Tobin J; Gunawardana J; Francis S; Gifford G; Gabrielli S; Gill A; Stevenson W; Talaulikar D; Gould C; Jain S; Birch S; Hertzberg M; Gandhi MK
Eur J Haematol; 2019 Sep; 103(3):200-207. PubMed ID: 31211907
[TBL] [Abstract][Full Text] [Related]
43. Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma.
Song JY; Nwangwu M; He TF; Zhang W; Meawad H; Bedell V; Murata-Collins J; Skrabek P; Nasr MR; Scott D; Godfrey J; Lee P; Chan WC; Weisenburger DD; Perry AM; Herrera AF
Haematologica; 2023 Aug; 108(8):2167-2177. PubMed ID: 36632739
[TBL] [Abstract][Full Text] [Related]
44. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Rosenwald A; Wright G; Chan WC; Connors JM; Campo E; Fisher RI; Gascoyne RD; Muller-Hermelink HK; Smeland EB; Giltnane JM; Hurt EM; Zhao H; Averett L; Yang L; Wilson WH; Jaffe ES; Simon R; Klausner RD; Powell J; Duffey PL; Longo DL; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Montserrat E; López-Guillermo A; Grogan TM; Miller TP; LeBlanc M; Ott G; Kvaloy S; Delabie J; Holte H; Krajci P; Stokke T; Staudt LM;
N Engl J Med; 2002 Jun; 346(25):1937-47. PubMed ID: 12075054
[TBL] [Abstract][Full Text] [Related]
45. A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDSC and Th17 cells in lymphoma progression.
Sun R; Zheng Z; Wang L; Cheng S; Shi Q; Qu B; Fu D; Leboeuf C; Zhao Y; Ye J; Janin A; Zhao WL
Mol Oncol; 2021 Jan; 15(1):246-261. PubMed ID: 33107145
[TBL] [Abstract][Full Text] [Related]
46. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
48. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
49. Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma.
Merdan S; Subramanian K; Ayer T; Van Weyenbergh J; Chang A; Koff JL; Flowers C
Blood Cancer J; 2021 Jan; 11(1):2. PubMed ID: 33414466
[TBL] [Abstract][Full Text] [Related]
50. Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome.
Barrans SL; Crouch S; Care MA; Worrillow L; Smith A; Patmore R; Westhead DR; Tooze R; Roman E; Jack AS
Br J Haematol; 2012 Nov; 159(4):441-53. PubMed ID: 22970711
[TBL] [Abstract][Full Text] [Related]
51. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
52. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP.
Coutinho R; Clear AJ; Mazzola E; Owen A; Greaves P; Wilson A; Matthews J; Lee A; Alvarez R; da Silva MG; Cabeçadas J; Neuberg D; Calaminici M; Gribben JG
Haematologica; 2015 Mar; 100(3):363-9. PubMed ID: 25425693
[TBL] [Abstract][Full Text] [Related]
53. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.
Puleo F; Nicolle R; Blum Y; Cros J; Marisa L; Demetter P; Quertinmont E; Svrcek M; Elarouci N; Iovanna J; Franchimont D; Verset L; Galdon MG; Devière J; de Reyniès A; Laurent-Puig P; Van Laethem JL; Bachet JB; Maréchal R
Gastroenterology; 2018 Dec; 155(6):1999-2013.e3. PubMed ID: 30165049
[TBL] [Abstract][Full Text] [Related]
54. Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Tian Z; Wang Z; Chen Y; Qu S; Liu C; Chen F; Ma L; Zhu J
Med Sci Monit; 2020 Mar; 26():e922159. PubMed ID: 32231177
[TBL] [Abstract][Full Text] [Related]
55. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
56. A robust panel based on tumour microenvironment genes for prognostic prediction and tailoring therapies in stage I-III colon cancer.
Zhou R; Zeng D; Zhang J; Sun H; Wu J; Li N; Liang L; Shi M; Bin J; Liao Y; Huang N; Liao W
EBioMedicine; 2019 Apr; 42():420-430. PubMed ID: 30917936
[TBL] [Abstract][Full Text] [Related]
57. Development of a Reproducible Prognostic Gene Signature to Predict the Clinical Outcome in Patients with Diffuse Large B-Cell Lymphoma.
Zamani-Ahmadmahmudi M; Nassiri SM
Sci Rep; 2019 Aug; 9(1):12198. PubMed ID: 31434961
[TBL] [Abstract][Full Text] [Related]
58. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
59. Transcriptome sequencing of archived lymphoma specimens is feasible and clinically relevant using exome capture technology.
Skaftason A; Qu Y; Abdulla M; Nordlund J; Berglund M; Ednersson SB; Andersson PO; Enblad G; Amini RM; Rosenquist R; Mansouri L
Genes Chromosomes Cancer; 2022 Jan; 61(1):27-36. PubMed ID: 34647650
[TBL] [Abstract][Full Text] [Related]
60. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL.
Xu-Monette ZY; Li Y; Snyder T; Yu T; Lu T; Tzankov A; Visco C; Bhagat G; Qian W; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Wang Y; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Fan X; van Krieken JH; Piris MA; Winter JN; Au Q; Kirsch I; Zhang M; Shaughnessy J; Xu B; Young KH
Clin Cancer Res; 2023 Dec; 29(23):4808-4821. PubMed ID: 37728879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
